Neuromodulation—Who, What, When, Where and Why? (2009)

No AccessJournal of UrologyEditorial1 Jan 2010Neuromodulation—Who, What, When, Where and Why?is companion ofLong-Term Outcomes of Urgency-Frequency Syndrome Due to Painful Bladder Syndrome Treated With Sacral Neuromodulation and Analysis of FailuresLong-Term Durability of Percutaneous Tibial Nerve Stimulation for the Treatment of Overactive Bladder Robert Mayer Robert MayerRobert Mayer Financial interest and/or other relationship with American Medical Systems, Bioform, AbbyMoore Medical, Taris Biomedical, Pfizer and Allergan. More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2009.10.053AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "Neuromodulation—Who, What, When, Where and Why?." The Journal of Urology, 183(1), pp. 17–18 References 1 : Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol2009; 19: 380. Google Scholar 2 : A review of adherence to drug therapy in patients with overactive bladder. BJU Int2008; 102: 774. Google Scholar 3 : Sacral nerve stimulation for neuromodulation of the lower urinary tract. Neurourol Urodyn2008; 27: 28. Google Scholar 4 : Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence. 4th International Consultation on Incontinence. Paris: Health Publication Ltd2009. Google Scholar 5 : Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults. Cochrane Database Syst Rev2009; 2. CD004202. Google Scholar 6 : Neuromodulation 10 years on: how widely should we use this technique in bladder dysfunction?. Curr Opin Urol2009; 19: 375. Google Scholar 7 : The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?. BJU Int2009; . [Epub ahead of print]. Google Scholar 8 : Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the Overactive Bladder Innovative Therapy trial. J Urol2009; 182: 1055. Link, Google Scholar 9 : Sacral nerve stimulation for voiding dysfunction: one institution's 11-year experience. Neurourol Urodyn2007; 26: 19. Google Scholar Department of Urology, University of Rochester, Rochester, New York© 2010 by American Urological AssociationFiguresReferencesRelatedDetailsRelated articlesJournal of Urology13 Nov 2009Long-Term Outcomes of Urgency-Frequency Syndrome Due to Painful Bladder Syndrome Treated With Sacral Neuromodulation and Analysis of FailuresJournal of Urology13 Nov 2009Long-Term Durability of Percutaneous Tibial Nerve Stimulation for the Treatment of Overactive Bladder Volume 183Issue 1January 2010Page: 17-18 Advertisement Copyright & Permissions© 2010 by American Urological AssociationMetricsAuthor Information Robert Mayer Financial interest and/or other relationship with American Medical Systems, Bioform, AbbyMoore Medical, Taris Biomedical, Pfizer and Allergan. More articles by this author Expand All Advertisement PDF downloadLoading ...